|
May 1
|
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
|
|
Apr 1
|
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million
|
|
Mar 22
|
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
|
|
Apr 25
|
InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary
|
|
Apr 24
|
InterCure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In Israel
|